title: Etoposide and mitomycin in the treatment of non-small-cell lung cancer. A phase I-II evaluation.
abstract: Sixty-five patients (20 patients who had had prior radiotherapy and 45 patients who had not had prior radiotherapy) were entered into a study evaluating escalating doses of etoposide and mitomycin in the treatment of non-small-cell lung cancer (NSCLC). Twenty-two percent of patients who had not received prior radiotherapy responded to the chemotherapy, compared with 5% of patients who had received prior radiotherapy. The best response rate and median survival time was 30% and 31.9 weeks, respectively, seen in three of 10 patients receiving mitomycin 10 mg/M2 i.v. day 1 and etoposide 100 mg/M2 i.v. days 1-3. The major toxicity was hematologic--mainly leukopenia, in 59% of patients who had had no prior radiation therapy and were receiving mitomycin 10 mg/M2 i.v. day 1 and etoposide 150 mg/M2 i.v. days 1-3 (grade 3 and 4 hematologic toxicity). The mitomycin-etoposide drug combination has some activity in patients with NSCLC who have not received prior radiotherapy. The recommended starting dose is mitomycin 10 mg/M2 i.v. day 1 and etoposide 100 mg/M2 i.v. days 1-3, administered every 4 weeks.
authors.affiliation: Johns Hopkins Oncology Center, Baltimore, MD 21205.
authors.forename: D S
authors.initials: DS
authors.lastname: Ettinger
authors.forename: J D
authors.initials: JD
authors.lastname: Bitran
authors.forename: R L
authors.initials: RL
authors.lastname: Comis
authors.forename: C J
authors.initials: CJ
authors.lastname: Langer
authors.forename: K V
authors.initials: KV
authors.lastname: Harwood
authors.forename: C L
authors.initials: CL
authors.lastname: Harris
authors.forename: J H
authors.initials: JH
authors.lastname: Keller
authors.forename: M
authors.initials: M
authors.lastname: Losada
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage* / Q000009:adverse effects; D012074:Remission Induction; D015996:Survival Rate; D013997:Time Factors
chemical_list: D008937:Mitomycins; D005047:Etoposide